On Tuesday (7/9/19) in New Orleans, the U.S. Court of Appeals for the Fifth Circuit heard oral arguments on whether a federal judge in Texas made the correct decision in December when he struck down as unconstitutional the Affordable Care Act (ACA). What's at stake? What's the immediate impact? What can be done?
Mental health issues are a big part of our patient education programs. Ask the Expert and mental health first aid instructor Debbie de la Riva, LPC, your questions on Thursday, May 30, at 8PM EDT, on the B Connected app.
A win for the hemophilia community. The CMS final 2020 payment notice does not ban accumulator programs completely, but it does limit their application to drugs with equally effective generic alternatives. As there are no generic drugs for hemophilia, all of the currently available drugs used to treat it should be exempt.
Many members of our community may discover their insurance company uses an a copay accumulator adjuster program (CAAP) to reimburse less for medication by pushing more “cost sharing” onto the patient. This slide presentation from the National Hemophilia Foundation explains the issue in detail.
Insurance companies have started to introduce something called co-pay accumulator programs that have the potential to make hemophilia treatments unaffordable for many patients. It’s of utmost importance that everyone potentially affected understand what they are, what kind of impact they may have on access to care, and what we all can do about them.